5-Amino-1MQ for fat loss: hype vs. what the data shows

What did @coachcam.peps3 actually say?

The creator's core argument is that 5-amino-1MQ supports fat loss not by acting as a stimulant, but by inhibiting NNMT, an enzyme he calls "a metabolic brake in the body." He claims overexpression of NNMT reduces NAD+ availability, decreases thermogenesis, and increases fat storage. Block the enzyme, he argues, and you restore metabolic function, activate SIRT1, and make fat cells more metabolically active. He was also careful to add that users still need to eat in a deficit, sleep well, and exercise. That disclaimer matters, and it's more honest than most peptide content on TikTok.

He also rattled off a list of over-the-counter supplements, including magnesium, B vitamins, TMG, L-carnitine, NAD+, and urolithin A, as compounds that can support the metabolic environment where 5-amino-1MQ operates. No dosing advice was given, which is worth noting.

Does the science back this up?

Some of it, yes. But the gap between mouse studies and human outcomes is enormous here, and the creator glosses over it entirely. The foundational NNMT research exists and it is real, but it is nowhere near as clean as this video implies.

NNMT is a real enzyme that methylates nicotinamide, consuming SAM (S-adenosylmethionine) in the process and reducing NAD+ precursor availability. Researchers have shown that NNMT is overexpressed in adipose tissue in obese individuals. A 2014 study by Kruse et al. in Nature Communications demonstrated that NNMT knockdown in mice reduced adiposity and improved insulin sensitivity. That is the foundational paper underpinning most 5-amino-1MQ enthusiasm. However, 5-amino-1MQ itself was only characterized as a selective NNMT inhibitor in a 2021 paper by Neelakantan et al. in Nature Communications, where it showed fat mass reduction in diet-induced obese mice. That is one mouse study. There are no published randomized controlled trials in humans for 5-amino-1MQ. The SIRT1 activation claim follows logically from NAD+ biology, as SIRT1 is an NAD+-dependent deacetylase, but calling this effect "meaningful" in humans from this compound is speculative at best.

What did they get wrong (or right)?

He got the mechanism directionally right but oversold the certainty. He also fumbled the enzyme name. He says NNMT stands for "nicotinamide and methyltransferase" when the correct expansion is nicotinamide N-methyltransferase. That is a small error, but for a video tagged with "medicine" and "research," it suggests the creator is working from secondhand sources.

What he got right is the general NNMT biology. The enzyme does consume methyl groups, it is associated with metabolic dysfunction in adipose tissue, and inhibiting it has shown promise in preclinical models. His framing of 5-amino-1MQ as a metabolic optimizer rather than a direct fat burner is also more accurate than how most peptide sellers describe it. And his insistence that diet, sleep, and exercise remain necessary is genuinely responsible for this category of content.

What he got wrong is presenting mouse-study findings as if they are established human physiology. Saying your body is "better at burning stubborn fat, not so stubborn anymore, thanks to 5-amino-1MQ" is a confident human-outcome claim built on rodent data. That is a meaningful leap. He also lumps urolithin A into a supplement stack without noting it has a distinct mechanism and its own clinical evidence base, making the list feel less curated and more like a shotgun approach.

What should you actually know?

5-amino-1MQ is an unregulated research compound with no FDA approval, no established human dosing, and no published human clinical trials as of mid-2025. The preclinical evidence is genuinely interesting, but interesting preclinical data fails to translate to humans constantly in metabolic research. Anyone offering this compound as a telehealth product should be prepared to explain clearly that they are operating in a research context, not prescribing a proven therapy.

The NNMT inhibition pathway is a legitimate area of metabolic research. A 2022 review by Schmeisser et al. in Aging Cell confirmed that NNMT activity increases with age and may contribute to metabolic decline, giving some biological plausibility to the approach. But plausibility is not efficacy. If you are considering this compound, you should understand that you are essentially participating in an n-of-1 experiment, and the safety profile in humans is not fully characterized. The supplement additions the creator mentions, particularly methylated B vitamins, TMG, and NAD+ precursors, have more direct human evidence and lower risk profiles. If metabolic support is the goal, those are a more evidence-grounded starting point.